Early Detection. Precision Diagnostics. Better Clinical Decisions- all from a simple blood test.
5Q Spectra Corporation is advancing prostate cancer detection through proprietary CTC-sense technology platform.
What the PSA Can't Tell You
5Q’s “PSB” the next step in prostate cancer detection does tell you!
PSA gives you a signal — but not the full picture.
The next step is clarity. The PSB – 5Q’s Prostate Dx™ test goes beyond PSA by analyzing prostate-specific biomarkers to help interpret what your results actually mean. It provides a more reliable assessment of the likelihood of prostate cancer, helping distinguish real risk from unnecessary concern.
The current pathway creates anxiety, cost, and unnecessary procedures.
ProstateDx™ is a simple blood test designed to detect signals from biologically active prostate cancer cells.
Instead of guessing based on indirect markers, ProstateDx™ helps identify which men are more likely to have clinically significant cancer and which men can safely continue monitoring.
Built for the exact moment when uncertainty begins.
Monitor
If results show a low likelihood of clinically significant prostate cancer, the recommended path may be continued monitoring. This typically includes routine PSA testing and periodic follow-up to keep watch on prostate health while avoiding unnecessary procedures.
Escalate
If results suggest increasing risk, your doctor may recommend further evaluation such as advanced imaging, additional biomarker testing, or a targeted biopsy to better understand what is changing.
Act
If testing indicates a high likelihood of clinically significant cancer, your physician can move quickly toward diagnostic confirmation and treatment planning to address disease that requires intervention.
A simple 3-Step process.
ProstateDx™ is a physician-ordered blood test that measures biologically active prostate cancer cells to improve decision-making after an elevated PSA.
Built for the exact moment when uncertainty begins.
When the biology is clear, everyone benefits.
5Q's blood-based approach creates better outcomes at every level of care from the exam room to the bottom line.
For the Clinician
A biologically grounded decision. No more ordering a biopsy based on a number alone. Confidence that the workup is justified or that monitoring is safe.
For the Patient
Fewer unnecessary biopsies. Less prolonged anxiety. A clear next step, not a waiting game. Knowing the test looked at the biology, not just a number.
For the Health System
Reduced downstream costs from unnecessary procedures. Better resource allocation. A defensible, evidence-based diagnostic workflow.
Indecision Is a Decision
And It Has Consequences
Without a better diagnostic tool, the current cycle continues:
elevated PSA triggers workup, workup triggers anxiety, anxiety triggers biopsy, biopsy finds nothing actionable. Patients continue to be over-biopsied. Aggressive cancers continue to be detected later than they should be. The clinician continues to make high-stakes calls with low resolution data.
This is not a hypothetical risk. It is the current standard of care. ProstateDx™ exists to interrupt that cycle.
Have any questions?
What makes ProstateDx™ (PSB) different from traditional prostate cancer screening ?
Traditional prostate cancer screening starts and often stops with PSA, a useful but blunt tool. A high PSA can signal cancer, but it can also mean an enlarged prostate, inflammation, or simply nothing at all. It doesn't tell your doctor what is actually happening at a biological level. That uncertainty is what leads to unnecessary biopsies, prolonged anxiety, and in some cases, overtreatment of cancers that never needed to be touched. ProstateDx™ goes further. It measures biologically active prostate cancer cells in your blood — the actual biology — and translates that into a clear risk score. It's not guessing based on a number. It's reading the signal your body is already sending. The result is a smarter, less invasive path to the answer you actually need.
Is the test invasive?
Not at all. ProstateDx™ is a simple blood draw the same kind you'd get at any routine doctor's visit. No needles beyond that, no prep, no recovery time. That's exactly the point. Before ProstateDx™ the next step after an elevated PSA was often a biopsy, an uncomfortable, anxiety-inducing procedure that, up to 70% of the time, comes back negative. ProstateDx™ was built to change that. One blood draw can give your doctor the biological clarity they need, so a biopsy only happens when it truly should.
What do the results tell me?
ProstateDx™ gives you and your doctor a single, easy-to-understand risk score from 0 to 100 that estimates the likelihood of clinically significant prostate cancer. It's not a yes or no answer, but it is something far more useful: a biologically grounded signal that helps your doctor decide whether a biopsy is truly necessary. A lower score means you may be able to skip the biopsy altogether and simply continue monitoring. A higher score means your doctor has the confidence to act without second-guessing a number alone. Either way, you leave with clarity, not more uncertainty.
Who should consider this test?
Patients who have elevated or unclear screening results, family history concerns, or questions about cancer risk may benefit from additional biological insight. Your physician can help determine whether the test is appropriate for your situation.
ProstateDx™ is a laboratory developed test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Testing is performed as a laboratory developed test (LDT) under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to conduct high-complexity testing.